BioCryst presents real-world data at EAACI Congress showing reduced attack rates in HAE patients with normal C1-inhibitor levels on ORLADEYO®.

BioCryst announces new real-world evidence showing reduced attack rates in HAE patients with normal C1-inhibitor levels after starting oral, once-daily ORLADEYO® (berotralstat). The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain. This new evidence may aid in better diagnosing and managing HAE patients with normal C1-inhibitor levels.